tolperisone HCl; tolperisone HCl; tolperisone HCl
Проводит Avigen
Страница компанииAV650-018: A Two-Part (Double-Blind Followed by Open-Label), Placebo Controlled, Randomized Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AV650 (Tolperisone HCl) in Subjects With Spasticity Associated With Multiple Sclerosis
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00532532/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование прекращено досрочно, новых участников не набирают.
- Возраст участников: 18–70 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 150 чел. во всех странах исследования.
- Центров в реестре: 5 в 3 городах. Список — ниже на странице.
- Плановая дата окончания (11.2008) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 10 · невключение: 24
Критерии включения
- Male or female subjects between 18 and 70 years of age (inclusive)
- Signed and dated informed consent
- Definite MS as per Poser or MacDonald Criteria (either relapsing remitting or secondary progressive course)
- Expanded Disability Status Score (EDSS) from 3.0 to 6.5 (inclusive) at Screening
- Stable MS for at least 30 days before screening
- Female of child bearing potential and male subjects whose partner is of child bearing potential who are willing to ensure that they or their partner use effective double-barrier contraception during the study and for 90 days thereafter
- If female, be neither pregnant nor nursing (Confirmation that the subject is not pregnant must be established by a negative serum hCG pregnancy test at baseline.)
- Significant spasticity in at least two muscle groups defined as a score of 2 or more on the Ashworth scale for each muscle group
- If a subject is on anti-spastic treatments, the dosage, frequency, and route of administration must be stable for at least 30 days before Screening
- If a subject is on MS treatments, the dosage, frequency, and route of administration must be stable for at least 30 days before Screening
Критерии невключения
- Subjects who have participated in another research study within 90 days of Screening
- Significant changes in anti-spasticity medications (dosage, frequency, or route of administration) within 30 days of Screening
- Known hypersensitivity to tolperisone HCl, its components, or other lidocaine/lidocaine-like products
- Use of tolperisone HCl within 30 days of screening
- Significant changes in MS treatments (dosage, frequency, or route of administration) within 30 days of Screening
- Spasticity due to neurological disorders other than MS
- Any psychiatric disorder or cognitive impairment that precludes fully informed consent or safe participation in the study
- Subjects who have suffered an acute relapse of MS or who continue to suffer from an acute relapse of MS within 90 days of Baseline
- History of alcohol or substance abuse within one year of Screening
- Concurrent clinically significant immunologic, pulmonary, renal, hepatic, or endocrine disease and/or other unstable or major disease other than MS
- Clinically significant cardiovascular disorders, such as ischemic heart disease, arrhythmias, poorly controlled hypertension, or acute myocardial infarction
- QT prolongation greater than 480 msec or greater than 450 msec if accompanied by a partial bundle branch block, or other ECG abnormality in the judgment of the Investigator
- Diastolic blood pressure <50mmHg or >105mmHg; heart rate <50 beats per minute (bpm) or >110bpm, after 3 minutes in a sitting position; heart rate by ECG <50bpm or >110bpm
- History of epilepsy (except childhood febrile seizures)
- Current malignancy or history of malignancy that has not been in remission for more than five years, except basal cell skin carcinoma and cervical cancer (with treatment)
- Female subject who is pregnant, nursing, or planning pregnancy during the course of the study
- Scheduled elective surgery or other procedures requiring general anesthesia during the study
- Subject who is terminally ill in the judgment of the Investigator
- Subject who is inappropriate for placebo medication in the judgment of the Investigator
- Systemic corticosteroid therapy within 28 days of randomization, with the exception of inhaled medications for asthma
- Exacerbation of MS within 30 days of Baseline
- Regular levo-dopa therapy within 7 days of randomization
- Subjects taking antiarrhythmic medications
- Donation of blood during the study
Источник: ClinicalTrials.gov, NCT00532532 · запись обновлена в реестре 4 ноября 2008.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 1
- To determine the long-term safety and tolerability of AV650 (tolperisone HCl) in subjects with spasticity associated with MS — 38 weeks
Цель исследования
A drug called AV650 (tolperisone HCl) will be given to patients who have spasticity associated with multiple sclerosis. This study has three purposes:
1. To determine whether AV650 is safe for patients with multiple sclerosis;
2. To gather some early evidence as to whether AV650 is effective in treating spasticity in patients with multiple sclerosis; and,
3. To assess what the body does with AV650 once it is ingested (Germany and Czech Republic sites only).
Где проходит
5 центров в 3 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00532532 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.